Russell Investments Group Ltd. Reduces Holdings in Progyny, Inc. (NASDAQ:PGNY)

Russell Investments Group Ltd. lessened its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 75.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 50,548 shares of the company’s stock after selling 154,125 shares during the quarter. Russell Investments Group Ltd. owned about 0.06% of Progyny worth $872,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. River Road Asset Management LLC purchased a new stake in Progyny in the fourth quarter valued at $25,529,000. Pacer Advisors Inc. raised its holdings in Progyny by 47.5% in the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock valued at $63,414,000 after buying an additional 1,183,558 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its position in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after buying an additional 695,740 shares during the last quarter. Barclays PLC boosted its stake in Progyny by 530.4% during the third quarter. Barclays PLC now owns 706,157 shares of the company’s stock worth $11,835,000 after buying an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. increased its position in shares of Progyny by 52.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock valued at $22,989,000 after acquiring an additional 456,853 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

PGNY stock opened at $21.37 on Tuesday. The company’s 50 day moving average price is $21.93 and its 200 day moving average price is $18.92. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 36.85, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $33.84.

Analyst Upgrades and Downgrades

PGNY has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Bank of America lifted their price objective on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Finally, Canaccord Genuity Group lifted their target price on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.